- The disease
- A chronic anal fissure is a persistent, non-healing tear in the skin lining the anal canal, typically causing pain during and after bowel movements. It is distinct from an acute fissure in that it has been present for more than approximately six to eight weeks and often involves structural changes in the surrounding tissue. The condition can significantly reduce quality of life, and many patients seek alternatives to surgical management. Conservative treatments, including topical agents, are generally considered before surgical options.
- What the asset is trying to do
- Nitroglycerin is a well-established vasodilator that releases nitric oxide (NO) when absorbed through the skin. In the anal fissure setting, topical application is intended to relax the internal anal sphincter, which is thought to be in a state of elevated tone in patients with chronic fissures, thereby improving blood flow to the area and supporting tissue healing. This is a topical formulation of a long-established compound; Acrux describes the asset as a generic topical vasodilator. The Abbreviated New Drug Application (ANDA) pathway indicates Acrux is seeking approval on the basis of bioequivalence to a previously approved reference product rather than new clinical efficacy data.
- What the trial is measuring, and why it matters
- Because this asset is being pursued via the ANDA (generic drug) regulatory pathway with the US Food and Drug Administration (FDA), the primary regulatory requirement is demonstration of bioequivalence to the reference listed drug rather than a new clinical efficacy trial. Bioequivalence studies typically measure pharmacokinetic parameters such as the rate and extent of drug absorption. The specific study design and endpoints for the Acrux ANDA submission are .
- Efficacy benchmarks in this setting
- The reference listed drug for topical nitroglycerin in chronic anal fissure is Rectiv (nitroglycerin 0.4% ointment), which received FDA approval in 2011 (per FDA Orange Book). In clinical studies supporting Rectiv's approval, the product demonstrated statistically significant reduction in pain associated with chronic anal fissure compared to placebo; the specific response rates and pain reduction figures from those studies are (source required). Published literature on topical nitroglycerin across multiple trials has reported healing rates and headache as a common side effect, but specific pooled figures from a named, citable source are . As this asset is pursuing an ANDA (generic equivalence) pathway, any early-stage figures from its own studies are not statistically comparable to efficacy data from the reference product's clinical program.